Mersana 
Welcome,         Profile    Billing    Logout  
 7 Products   9 Diseases   7 Products   3 Trials   299 News 


123»
  • ||||||||||  calotatug ginistinag (XMT-2056) / Mersana, GSK
    XMT-2056, a HER2-targeted immunosynthen STING agonist antibody-drug conjugate, induces anti-tumor activity at low doses in preclinical models (Exhibit Halls AB - George R. Brown Convention Center) -  Oct 4, 2024 - Abstract #SITC2024SITC_1099;    
    P1
    We further demonstrate that XMT-2056, when administered to mice at very low doses, activates STING signaling in tumors and upregulates immune pathway genes, including PD-L1, resulting in significant tumor growth inhibition. Conclusions Together, these results underscore the therapeutic potential of XMT-2056 in treating tumors with various levels of HER2-expression and support its ongoing clinical exploration in a Phase 1 dose escalation study in patients with solid tumors expressing HER2 (NCT05514717).
  • ||||||||||  calotatug ginistinag (XMT-2056) / Mersana, GSK
    Enrollment open, Trial completion date, Trial primary completion date, Metastases:  MER-XMT-2056-1: A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 (clinicaltrials.gov) -  Feb 29, 2024   
    P1,  N=162, Recruiting, 
    Abstract is embargoed at this time. Suspended --> Recruiting | Trial completion date: Nov 2025 --> Apr 2027 | Trial primary completion date: Nov 2025 --> Apr 2027
  • ||||||||||  emiltatug ledadotin (XMT-1660) / Mersana
    Enrollment change, Trial completion date, Trial primary completion date:  A Study of XMT-1660 in Participants With Solid Tumors (clinicaltrials.gov) -  Feb 23, 2024   
    P1,  N=319, Recruiting, 
    Suspended --> Recruiting | Trial completion date: Nov 2025 --> Apr 2027 | Trial primary completion date: Nov 2025 --> Apr 2027 N=166 --> 319 | Trial completion date: Jan 2026 --> May 2027 | Trial primary completion date: Jan 2025 --> Dec 2026
  • ||||||||||  emiltatug ledadotin (XMT-1660) / Mersana
    Trial completion date, Trial primary completion date:  A Study of XMT-1660 in Participants With Solid Tumors (clinicaltrials.gov) -  Dec 15, 2023   
    P1,  N=166, Recruiting, 
  • ||||||||||  upifitamab rilsodotin (XMT-1536) / Mersana
    Enrollment closed, Phase classification:  Uplift: First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b (clinicaltrials.gov) -  Nov 13, 2023   
    P1/2,  N=523, Active, not recruiting, 
    N=166 --> 319 | Trial completion date: Jan 2026 --> May 2027 | Trial primary completion date: Jan 2025 --> Dec 2026 Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1/2
  • ||||||||||  upifitamab rilsodotin (XMT-1536) / Mersana
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT) (clinicaltrials.gov) -  Oct 26, 2023   
    P3,  N=20, Terminated, 
    Recruiting --> Active, not recruiting | Phase classification: P1b/2 --> P1/2 N=350 --> 20 | Trial completion date: Mar 2025 --> Sep 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2024 --> Sep 2023; Study Terminated by Sponsor
  • ||||||||||  upifitamab rilsodotin (XMT-1536) / Mersana
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Combination therapy:  UPGRADE: Study of Upifitamab Rilsodotin in Combination With Carboplatin in Participants With High-grade Serous Ovarian Cancer (clinicaltrials.gov) -  Oct 10, 2023   
    P1,  N=31, Terminated, 
    N=350 --> 20 | Trial completion date: Mar 2025 --> Sep 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2024 --> Sep 2023; Study Terminated by Sponsor N=48 --> 31 | Trial completion date: Mar 2025 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2024 --> Oct 2023; Study Terminated by Sponsor
  • ||||||||||  XMT-1592 / Mersana
    Enrollment change, Trial termination:  First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b (clinicaltrials.gov) -  Oct 6, 2023   
    P1b,  N=31, Terminated, 
    N=48 --> 31 | Trial completion date: Mar 2025 --> Oct 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2024 --> Oct 2023; Study Terminated by Sponsor N=120 --> 31 | Active, not recruiting --> Terminated; discontinued development program
  • ||||||||||  Antibody-Drug Conjugates in Gynecologic Cancer () -  Jun 1, 2023 - Abstract #ASCO2023ASCO_7154;    
    Like all anticancer treatments, the decision for a patient to undergo therapy with an ADC is a personal choice that balances the potential benefits with the side effects and requires thorough and compassionate support of their physician and care team and shared decision making. PRACTICAL APPLICATIONS: Enhanced understanding of carcinogenesis and underlying molecular biology has accelerated drug development, and antibody-drug conjugates (ADCs) represent recent improvements in targeted therapies for gynecologic cancer.ADCs are currently Food and Drug Administration approved in ovarian and cervical cancer, with ongoing research to improve outcomes in various settings and in combination with other agents.Several ADCs show promise in endometrial cancer and continued subtype-specific research is necessary to determine the best therapeutic approaches.Careful monitoring of treatment-related adverse events, including class-specific eye toxicity, is necessary to mitigate serious side effects of ADCs.
  • ||||||||||  Journal:  Antibody-Drug Conjugates in Gynecologic Cancer. (Pubmed Central) -  May 29, 2023   
    In cervical cancer, tisotumab vedotin, an ADC-targeting tissue factor, received FDA accelerated approval in September 2021 after the phase II innovaTV 204 trial...Trastuzumab-deruxtecan (T-DXd), an ADC targeting human epidermal growth factor receptor 2 (HER2), is currently approved for HER2-positive and HER2-low breast cancer and shows promise in endometrial cancer. Like all anticancer treatments, the decision for a patient to undergo therapy with an ADC is a personal choice that balances the potential benefits with the side effects and requires thorough and compassionate support of their physician and care team and shared decision making.
  • ||||||||||  MODULE 3: Novel Agents and Strategies Under Investigation for Advanced OC (Hilton Chicago; Grand Ballroom (Level 2)) -  May 26, 2023 - Abstract #ASCO2023ASCO_7074;    
    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, Merck, Mersana Therapeutics Inc, and Novocure Inc. Biological rationale for combining PARP inhibitors with immune checkpoint inhibitors for patients with advanced OC Emerging results from the Phase III DUO-O study of up-front durvalumab in combination with chemotherapy and bevacizumab followed by durvalumab, olaparib and bevacizumab as maintenance therapy; implications for clinical practice and ongoing research Other ongoing Phase III trials investigating the utility of front-line PARP inhibitors with immunotherapy for advanced OC (eg, ATHENA-COMBO, FIRST) Biological rationale for targeting the sodium-dependent phosphate transport protein NaPi2b in OC; mechanism of action of upifitamab rilsodotin (UpRi) Available efficacy and safety data with and ongoing investigation of UpRi for patients with OC Mechanism of action of tumor treating fields and biological rationale for their investigation in OC Early-phase efficacy and safety data with and ongoing investigation of tumor treating fields in combination with chemotherapy for advanced OC Other novel agents and strategies under investigation for OC
  • ||||||||||  Elahere (mirvetuximab soravtansine-gynx) / ImmunoGen, upifitamab rilsodotin (XMT-1536) / Mersana
    Correlating expression of NaPi2b and FRa in high grade serous ovarian cancer (HGSOC). (On Demand | Hall A; Poster Bd # 240) -  Apr 26, 2023 - Abstract #ASCO2023ASCO_2185;    
    Additionally, general NaPi2b prevalence and the correlation of expression between RNA and IHC suggest that NaPi2b may be a rational biomarker to integrate in RNA tumor panel testing. This research underscores the importance of early, comprehensive testing of all relevant biomarkers to guide therapy selection, and suggests that additional research is needed to evaluate the potential association between FRa and NaPi2b expression via IHC.
  • ||||||||||  mipasetamab uzoptirine (ADCT-601) / Overland ADCT BioPharma, XMT-1660 / Mersana, MRG004A / Lepu Med
    Journal:  Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology. (Pubmed Central) -  Mar 16, 2023   
    In a follow-up experiment, HCC-1954 tumor spheroids were treated with either an AlexaFluor647-labeled DAR1 or DAR2 PBD-based ADC to study the effect on tumor penetration. Significant improvement of tumor spheroid penetration was observed for the DAR1 ADC compared to the DAR2 ADC at an equal payload dose, underlining the potential of a lower DAR for ADCs bearing ultrapotent payloads.
  • ||||||||||  calotatug ginistinag (XMT-2056) / Mersana, GSK
    Trial suspension, Metastases:  MER-XMT-2056-1: A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 (clinicaltrials.gov) -  Mar 15, 2023   
    P1,  N=171, Suspended, 
    Significant improvement of tumor spheroid penetration was observed for the DAR1 ADC compared to the DAR2 ADC at an equal payload dose, underlining the potential of a lower DAR for ADCs bearing ultrapotent payloads. Recruiting --> Suspended
  • ||||||||||  emiltatug ledadotin (XMT-1660) / Mersana
    Phase classification:  A Study of XMT-1660 in Participants With Solid Tumors (clinicaltrials.gov) -  Feb 21, 2023   
    P1,  N=166, Recruiting, 
    This additional mechanism of action of XMT-2056 can potentially impact the overall anti-tumor immune responses in tumors infiltrated by Fc?RIII+ cells. Phase classification: P1b --> P1
  • ||||||||||  upifitamab rilsodotin (XMT-1536) / Mersana
    Upifitamab Rilsodotin (Ballroom B) -  Feb 1, 2023 - Abstract #SGO2023SGO_113;    
  • ||||||||||  calotatug ginistinag (XMT-2056) / Mersana, GSK
    Enrollment open, Trial initiation date, Metastases:  MER-XMT-2056-1: A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 (clinicaltrials.gov) -  Dec 6, 2022   
    P1,  N=144, Recruiting, 
    Legal entity responsible for the study Mersana Therapeutics. Not yet recruiting --> Recruiting | Initiation date: Sep 2022 --> Dec 2022